Causal Linkage Between Inflammatory Bowel Disease and Primary Sclerosing Cholangitis: A Two-Sample Mendelian Randomization Analysis

Ying Xie¹, Xuejie Chen²†, Minzi Deng²†, Yuhao Sun¹, Xiaoyan Wang²*, Jie Chen¹*, Changzheng Yuan³ and Therese Hesketh¹,⁴

¹Centre for Global Health, Zhejiang University School of Medicine, Hangzhou, China, ²Department of Gastroenterology, The Third Xiangya Hospital, Central South University, Changsha, China, ³Department of Big Data and Health Science, Zhejiang University School of Medicine, Hangzhou, China, ⁴Institute for Global Health, University College London, London, United Kingdom

Background: Observational studies suggest an association between inflammatory bowel disease (IBD) [including ulcerative colitis (UC) and Crohn’s disease (CD)] and Primary sclerosing cholangitis (PSC), but the causal association between the two diseases remains unclear.

Methods: We used two-sample Mendelian randomization (MR) to estimate the causal association between IBD and PSC. We chose single nucleotide polymorphisms (SNPs) data for analysis, obtained from previous genome-wide association studies (GWASs). Pleiotropy, heterogeneity, and sensitivity analyses were performed for quality control.

Results: We found that the causal associations between IBD (both UC and CD) and PSC were significant (e.g., IBD and PSC, Robust adjusted profile score (RAPS) OR = 1.29, 95% CI 1.16~1.44, p < 0.01; UC and PSC, RAPS OR = 1.40, 95% CI 1.23~1.58, p < 0.01; CD and PSC, RAPS OR = 1.13, 95% CI 1.02~1.26, p = 0.02). MR Egger, IVW, and ML tests found statistical heterogeneity between determined IV estimates. The leave-one-out analysis also indicated the sensitivity of the SNPs (e.g., IBD and PSC, MR-Egger Q = 644.30, p < 0.01; UC and PSC, MR-Egger Q = 378.30, p < 0.01; UC and PSC, MR-Egger Q = 538.50, p < 0.01).

Conclusion: MR analyses support the positive causal effect of IBD (including UC and CD) on PSC in a European population. We provide suggestions for preventing and treating the two diseases.

Keywords: inflammatory bowel disease, ulcerative colitis, Crohn's disease, mendelian randomization, primary sclerosing cholangitis
INTRODUCTION

Primary sclerosing cholangitis (PSC) is a rare, progressive cholestatic disease featuring impaired bile formation and chronic liver dysfunction, led by inflammation and fibrosis with a 0.77 per 100,000 person-years incidence rate (Molodecky et al., 2011; Karlsen et al., 2017; Dyson et al., 2018). Both genetic and environmental factors contribute to PSC, with the intestinal microbiome being considered as a pathogenetic factor. Inflammatory bowel diseases (IBDs) describe a series of chronic inflammatory disorders of the gastrointestinal tract including two main types: Crohn’s disease (CD) and ulcerative colitis (UC) (Rosen et al., 2015; Hodson, 2016).

It has been reported that IBD and PSC are closely associated. According to a comprehensive review, the prevalence of IBD in PSC has reached two-thirds (Karlsen et al., 2017). It has been observed that total colectomy can reduce the recrudescence risk of PSC by 50%, prior to or within liver transplantation (Lindström et al., 2018; Ricciuto et al., 2018). It has also been reported that the inflammatory type of PSC differs from UC or CD (Karlsen et al., 2017). Genetically, PSC appears to be more like an autoimmune condition compared with IBD (Liu et al., 2013). Although the striking association has been found for more than 50 years (Warren et al., 1966), the mechanisms for the relationships between the two diseases remain elusive.

The causal relationship between IBD and PSC is important in exploring the function of the disease, and thus in informing evidence for effective treatment. Randomized controlled trials (RCTs) are the most reliable method for determining causal inference in treatment studies. However, due to the requirements of the design and implementation, difficulty to control, and the consideration of ethics, RCTs are difficult to conduct. We used the Mendelian randomization (MR) analysis to explore the likely causal relevance between exposure and outcome, based on observational epidemiological studies.

Because gametes follow Mendelian rules of inheritance (parental alleles are randomly assigned to offspring), genetic variation is not affected by confounders such as environmental exposure, socioeconomic status, and behavior. Furthermore, genetic variation comes from parents, thus the association with outcomes is chronological. Therefore, MR can overcome the problems of confounding and reverse causality.

The instrumental variables (IVs) in the MR study rely on three core assumptions: (a) the genetic variant (either combined or isolated with other variants) is associated with the exposure; (b) the genetic variant is not associated with confounders that are either known or unknown; (c) there is no pathway from the genetic variant to outcomes that do not include the exposure. In MR research, it is difficult to obtain an accurate estimate of causal association without any one of the above assumptions.

Genome-wide association studies (GWAS) featuring large sample sizes make genetic variants available. Based on the previous GWAS, we selected single nucleotide polymorphisms (SNPs) that are strongly relevant to IBD (including UC and CD) as IVs. The effect of IVs on the exposures (IBD) and outcomes (PSC) was from two independent samples. We used two-sample MR and statistical methods to analyze the quantitative effects of IBD (UC, CD) on PSC.

MATERIALS AND METHODS

Data Source

More SNP sites related to IBD were screened out by GWAS results combined with literature reports. This study chose SNPs from publicly available GWAS data bases associated with exposures (IBD, including UC and CD). IBD-associated SNPs were derived from a GWAS meta-analysis study of IBD in the European Genome-phenome Archive (EGA). The statistics came from an extended cohort of 86,640 European individuals and 9,846 non-Europeans (Liu et al., 2015). Studies showed that most of the risk loci were shared across divergent populations (Teslovich et al., 2010; Okada et al., 2014; Liu et al., 2015). The SNPs associated with PSC were selected from the largest GWAS of PSC up to date, the European population, including 4,796 cases and 19,955 population controls. Quality control, like the Inverse variance weighted (IVW) fixed-effects meta-analysis, was performed to test the evidence of association across the GWAS and cohorts. Bayesian tests were conducted in both studies to identify loci with strong evidence.

SNP Selection

From the collection of SNPs in previous studies, we then set some standards for including eligible SNPs. We chose SNPs that were significantly associated with exposures ($p \leq 5e^{-8}$) and that had a certain probability of mutation (Minor allele frequency, MAF $\geq 5\%$), without reported loci coincidence or linkage disequilibrium (LD) ($R^2 < 0.001$). The palindromic SNPs which can introduce ambiguity into the identity of the effect allele in the exposure GWAS were also excluded. The SNPs that were both related to PSC and IBD were the excluded to meet the third core assumption, eliminating other pathways from the genetic variant to outcomes that do not include the exposure.

Effect Size Estimate

We estimated the causal association between exposures (IBD, UC and CD) and outcomes (PSC) with Inverse variance weighted (IVW), MR Egger, Weighted median (WM), Robust adjusted profile score (MR. RAPS), and Maximum likelihood (ML). IVW takes the inverse variance of each study as the weight to calculate the weighted average of effect sizes, to summarize the effect sizes of multiple independent studies (Lee et al., 2016). We also performed the Weighted median estimator (WME), with which causal effects can be accurately estimated with more than 50% weight using IVs when doing the analysis (Bowden et al., 2016a). A newly developed analysis called Robust adjusted profile score (MR. RAPS) considering the measurement error in SNP-exposure effects was conducted to reduce bias from weak IVs (Zhao et al., 2019). Maximum likelihood maximizing the likelihood function to estimate the probability distribution parameters was also used as a reference traditional method (Milligan, 2003). However, due to potential pleiotropic effects, the genetic variants may influence the outcome in an additional...
way, thus causing a bias. Therefore, we used MR-Egger regression as well, the slope of which can estimate the magnitude of directional pleiotropy. The MR-Steiger directionality test is used to test the causal direction between the hypothesized exposure and outcomes as a verification of the reliability of the results (Hemani et al., 2017). The results were presented in odds ratios (OR) and 95% confidence intervals (CI). A two-sided p-value was considered statistically significant when it was less than 0.05 (Figure 1). All statistical analyses were performed in R 3.4.2 with the package “TwoSampleMR.”

**Sensitivity Analyses**

In the MR analysis, it is necessary to consider whether SNPs, as instrumental variables, associate with other exposures. We used MR-Egger to test pleiotropy, verifying whether a single locus affects multiple phenotypes. The “Leave-one-out sensitivity analysis” algorithm is used as sensitivity analyses. With non-specific SNPs eliminated, if the correlation between other instrumental variables and outcomes was still statistically significant, it indicates more sufficient evidence of the causal association between exposure and outcomes. By removing SNPs one by one, the results are reanalyzed to draw the forest map with a stable result intuitively judged (Supplementary Figures S1–S3). As for the heterogeneity analysis, we conducted it for MR Egger, Inverse variance weighted, and Maximum likelihood. Heterogeneity was standardized with Cochran Q statistics; the weighted sum of the squared differences between the effect of each SNP and the summed effect of all SNPs. We also used a two-sided p-value and considered statistical significance at p < 0.05.

**RESULTS**

Based on the selection criteria above, we conducted linkage disequilibrium tests to choose SNPs that are both related to IBD and PSC. A total of 121, 76, and 104 SNPs were selected as IVs for IBD, UC, and CD, respectively. We then excluded 17 palindromic SNPs (nine for IBD, three for UC, and five for CD). Finally, we included 112, 73 m and 99 SNPs for IBD, UC, and CD, respectively (Supplementary Tables S4–S6).

The causal associations between IBD (UC, CD) and PSC were not accordant among the five methods. The RAPS indicated that IBD (both UC and CD) was significantly associated with PSC (IBD and PSC, RAPS OR = 1.29, 95% CI 1.16–1.44, p < 0.01; UC and PSC, RAPS OR = 1.40, 95% CI 1.23–1.58, p < 0.01; CD and PSC RAPS OR = 1.13, 95% CI 1.02–1.26, p = 0.02) (Table 1). However, using MR-Egger, none were significantly associated with PSC (For IBD, OR = 1.16, 95% CI 0.82–1.63, p = 0.41; UC, OR = 1.13, 95% CI 0.80–1.61, p = 0.50; CD, OR = 1.06, 95% CI 0.75–1.50, p = 0.74) (Table 1). When all genetic variants are valid, the causal effect may be underestimated due to the inflated type I error (Bowden et al., 2016b). Additionally, ML, WM showed the significant associations between UC, CD, and PSC while IVW did not reveal the associations between CD and PSC (Table 1). Based on the above five analyses, we concluded that the causal association between IBD and PSC were significant.

Pleiotropy, heterogeneity, and sensitivity analyses were performed for quality control. We used MR-Egger regression to test the pleiotropy, finding an unlikely bias caused by horizontal pleiotropy (IBD p = 0.48, UC p = 1.03, CD p = 0.72) (Table 2). To test the heterogeneity, we conducted MR Egger,IVW, and
ML, finding statistical heterogeneity between determined IV estimates (e.g., For IBD, MR-Egger Q = 644.30, \( p < 0.01 \); For UC, MR-Egger Q = 378.3, \( p < 0.01 \); For UC, MR-Egger Q = 538.50, \( p < 0.01 \))(Table 2). For sensitivity, we conducted a Leave-one-out sensitivity analysis, finding that the MR estimates were reasonable considering the effect of single SNPs (Supplementary Figures S1–S3). Additionally, the MR-Steiger test supported a positive causal correlation between IBD (UC, CD) and PSC, also identifying IVs’ affecting susceptibility to IBD traits and PSC. These results indicate the powerful relevance of MR assumption and the weak bias in the analysis.

**DISCUSSION**

To our knowledge, it is the first study to illustrate the causal relationship between IBD (UC, CD) and PSC using MR and GWAS. We found that IBD (including UC and CD) had a causal association with PSC, indicating that they may have a similar pathogenesis.

Several hypotheses have been proposed over the years, to explain the mechanisms of the model (Karlsen, 2016). An early RCT found that a small bowel bacterial overgrowth is associated with bile duct proliferation and destruction. Hypotheses based on the “leaky gut concept” indicated that bacteria and bacterial products could pass through damaged mucosa in IBD into the portal circulation (Lichtman et al., 1991). A review also reported that gut-derived mucosal T-cells expressing \( \alpha 4\beta 7 \) would contribute to biliary inflammation. Barrier functions like the expression of pathogen pattern receptors are similar between the biliary and gut epithelium. The receptor CXCR6, is found to have a higher expression on liver-infiltrating and gut-infiltrating lymphocytes. Blocking the receptors is a developing treatment for inflammation (Adams et al., 2008). Another hypothesis suggests the possibility of FtsZ and TBB-5 antigens deriving from colonic content, which may drive the biliary inflammation. This is related to an abnormal immune response to intestinal microorganisms in susceptible individuals (Terjung et al., 2010). In summary, the association may result from hyperreactive bile duct proliferation, aberrant increased enterohepatic circulation pathogen-associated
molecular patterns (PAMPs), or an abnormal immune response (Tabibian et al., 2013).

All five MR methods indicated a significant relationship between UC and PSC. Another study also reported the strong association of PSC with UC (90%) (Adams et al., 2008). As for CD, MR Egger, IVW showed no significant relationship between CD and PSC, while the other three methods revealed the causal relationship. MR Egger and IVW are similar, both using the inverse of the outcome variance (Se²) as the weight to carry out the fitting. The biggest difference between them is whether or not to consider the intercept term in the regression. Because of the low statistical power of MR-Egger, we usually focus on the consistency of the direction rather than the significance of estimates (Yeung and Schooling, 2020). From Supplementary Figures S1–S3, the consistent direction can be intuitively judged. Thus, we conclude that both UC and CD have a significant relationship with PSC.

In the Leave-one-out sensitivity analysis, we also found the specific SNPs that are strongly related to the disease (rs9836293 and rs2836883) for IBD; rs9836293 and rs2836883 for UC; rs31979999 for PSC). A previous study reported that the chromosome 3 SNP (rs31979999) is in the MST1 (Macrophage Stimulating 1) gene and is associated with MST1 protein levels. This SNP (rs31979999) can induce IBD by regulating the protein level of the Macrophage Stimulating Protein (MSP) (Di Narzo et al., 2017). Our results may provide inspiration for possible mechanism analyses in the future.

The causal association of IBD and PSC could contribute to improvement in PSC diagnostics and therapy, as well as prevention for IBD patients. For PSC, the diagnostics and therapy should better include IBD as a factor for improvement. According to PSC guidelines in the United States and Europe (Valuing Integrity, 2009; Lindor et al., 2015), major detection includes markers of cholestasis, bile duct lesions, and structuring on cholangiography with Magnetic resonance cholangiopancreatography (MRCP), along with a liver biopsy. Apart from these diagnostic investigations, we suggest regular colonoscopy surveillance for detecting IBD. For PSC patients with or without IBD, the clinical treatment and follow-up may be different. For example, clinical trials have tested the positive effect of antibiotics in PSC treatment (Tabibian et al., 2013). However, we should consider the potential consequent disturbance of gut microbiota (Karlsen, 2016), especially for IBD patients. For IBD, measures should be taken to prevent PSC at the very beginning. PSC-IBD has become an important public health issue due to the increased risk of malignancy (Rossi et al., 2016). Thus, regular physical examinations of PSC signs and symptoms are necessary for IBD patients. Currently, gut microbial signatures have been reported for their discriminatory function of determining early-stage PSC in IBD (Tabibian et al., 2013; Karlsen, 2016). Admittedly, the complex physiological machinery between IBD and PSC goes far beyond such simple models. Further studies are also needed to identify a potential mechanism for the association between IBD and PSC, to inform disease prevention.

Our study has several limitations. First, the SNP statistics we used were from a mixed population, 89.8% (86,640 in 96,486) of Europeans. However, the selected SNPs can explain 0.085 for IBD, 0.044 for UC, and 0.105 for CD of the phenotypic variation. Accordingly, the model fitness of PSC was also acceptable (0.06, 0.07, and 0.04). Second, although a series of sensitivity analyses have been conducted, we cannot guarantee that each SNP site meets the three basic conditions as instrumental variables. Considering the known confounding factors, we checked the confounders including smoking, drinking, and obesity and eliminated relative IVs. Admittedly, the influence of unknown possible confounders inevitably affects causal inference. Third, the MR model is based on the assumption of a linear effect association between exposure and outcome. Limited by the summary statistics, we did not perform a non-linearity of the association, which may be appropriate in some cases. Lastly, we found statistical heterogeneity between determined IV estimates, which may require further discussion (Supplementary Tables S4–S6).

CONCLUSION

MR analyses support the positive causal effect of IBD (including UC and CD) on PSC in the European population. Diagnostics and therapy improvement for PSC as well as the prevention of IBD should be promoted in clinical practice.

DATA AVAILABILITY STATEMENT

The original contributions presented in the study are included in the article/Supplementary Material, further inquiries can be directed to the corresponding author/s.

AUTHOR CONTRIBUTIONS

XW and JC conceptualized and designed the study. YX, XC, and YS collected and analyzed the data in the study. YX and JC drafted the manuscript. All authors contributed to this article and approved the submitted version.

FUNDING

This work was supported by the National Natural Science Foundation of China (81970494) and Key Research and Development Program of Hunan Province (2019SK2041).

ACKNOWLEDGMENTS

We thank the blogger (Orange caramel) for helping us understand different MR methods.

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fgene.2021.649376/full#supplementary-material
REFERENCES

Adams, D. H., Eksteen, B., and Curbishley, S. M. (2008). Immunology of the gut and liver: a love/hate relationship. Gut 57, 838–848. doi: 10.1136/gut.2007.122168

Bowden, J., Davey Smith, G., Haycock, P. C., and Burgess, S. (2016a). Consistent assessment of summary data for two-sample Mendelian randomization analyses using MR-Egger regression: the role of the I2 statistic. Int. J. Epidemiol. 45, 1961–1974. doi: 10.1093/ije/dyw220

Di Narzo, A. F., Telesco, S. E., Brodmerkel, C., Argmann, C., Peters, L. A., Li, K., Bowden, J., Del Greco, M. F., Minelli, C., Davey Smith, G., Haycock, P. C., and Burgess, S. (2016b). Assessing the suitability of summary data for two-sample Mendelian randomization analyses using MR-Egger regression: the role of the I2 statistic. Int. J. Epidemiol. 45, 1961–1974. doi: 10.1093/ije/dyw220

Hemani, G., Tilling, K., and Davey Smith, G. (2017). Orienting the causal relationship between imprecisely measured traits using GWAS summary data. PLoS Genet. 13:e1007081. doi: 10.1371/journal.pgen.1007081

Hudson, R. (2016). Inflammatory bowel disease. Nature 540:397. doi: 10.1038/540397a

Karlsen, T. H. (2016). Primary sclerosing cholangitis: 50 years of a gut-liver relationship and still no love? Gut 65, 1579–1581. doi: 10.1136/gutjnl-2016-312137

Karlsen, T. H., Folseraas, T., Thorburn, D., and Vesterhus, M. (2017). Primary sclerosing cholangitis– a comprehensive review. J. Hepatol. 67, 1298–1323. doi: 10.1016/j.jhep.2017.07.022

Lee, C. H., Cook, S., Lee, J. S., and Han, B. (2016). Comparison of two meta-analysis methods: inverse-variance-weighted average and weighted sum of z-scores. Genomics Inform. 14, 173–180. doi: 10.5808/GI.2016.14.4.173

Lichtman, S. N., Keku, J., Clark, R. L., Schwab, J. H., and Sartor, R. B. (1991). Bilary tract disease in rats with experimental small bowel bacterial overgrowth. Hepatology 13, 766–772. doi: 10.1002/hep.1840130425

Lindor, K. D., Kowdle, K. V., and Harrison, M. E. (2015). ACG clinical guideline: primary sclerosing cholangitis. Am. J. Gastroenterol. 110, 646–659; quiz660. doi: 10.1038/ajg.2015.112

Lindström, L., Jørgensen, K. K., Boberg, K. M., Castedal, M., Rasmussen, A., Rostved, A. A., et al. (2018). Risk factors and prognosis for recurrent primary sclerosing cholangitis after liver transplantation: a Nordic multicentre study. Scand. J. Gastroenterol. 53, 297–304. doi: 10.1002/ijg.265521.2017.1421705

Liu, J. Z., Hov, J. R., Folseraas, T., Ellinghaus, E., Rushbrook, S. M., Doncheva, N. T., et al. (2013). Dense genotyping of immune-related disease regions identifies nine new risk loci for primary sclerosing cholangitis. Nat. Genet. 45, 670–675. doi: 10.1038/ng.2616

Liu, J. Z., van Sommeren, S., Huang, H., Ng, S. C., Alberts, R., Takahashi, A., et al. (2015). Association analyses identify 38 susceptibility loci for inflammatory bowel disease and highlight shared genetic risk across populations. Nat. Genet. 47, 979–986. doi: 10.1038/ng.3359

Milligan, B. G. (2003). Maximum-likelihood estimation of relatedness. Genetics 163, 1153–1167.

Molodecky, N. A., Kareemii, H., Parab, R., Barkema, H. W., Quan, H., Myers, R. P., et al. (2011). Incidence of primary sclerosing cholangitis: a systematic review and meta-analysis. Hepatology 53, 1590–1599. doi: 10.1002/hep.24247

Okada, Y., Wu, D., Trynka, G., Raj, T., Terao, C., Ikari, K., et al. (2014). Genetics of rheumatoid arthritis contributes to biology and drug discovery. Nature 506, 376–381. doi: 10.1038/nature12873

Riccuito, A., Kamath, B. M., and Griffiths, A. M. (2018). The IBDC and PSC phenotypes of PSC-IBD. Curr. Gastroenterol. Rep. 20, 16. doi: 10.1007/s11894-018-0620-2

Rosen, M. J., Dhawan, A., and Saeed, S. A. (2015). Inflammatory bowel disease in children and adolescents. JAMA Pediatr. 169, 1053–1060. doi: 10.1001/jamapediatrics.2015.1982

Rossi, R. E., Conte, D., and Massironi, S. (2016). Primary sclerosing cholangitis associated with inflammatory bowel disease: an update. Eur. J. Gastroenterol. Hepatol. 28, 123–131. doi: 10.1097/MEG.0000000000000532

Tahbibi, J. H., Talwalkar, J. A., and Lindor, K. D. (2013). Role of the microbiota and antibiotics in primary sclerosing cholangitis. Biomed Res. Int. 2013:389537. doi: 10.1155/2013/389537

Terjung, B., Söhne, J., Lechtenberg, B., Gottwein, J., Muenich, M., Herzog, V., et al. (2010). p-ANCAs in autoimmune liver disorders recognise human beta-tubulin isotype 5 and cross-react with microbial protein FtsZ. Gut 59, 808–816. doi: 10.1136/gut.2008.157818

Teslovich, T. M., Musnurro, K., Smith, A. V., Edmondson, A. C., Stylianou, I. M., Koseki, M., et al. (2010). Biological, clinical and population relevance of 95 loci for blood lipids. Nature 466, 707–713. doi: 10.1038/nature090270

Valuing Integrity (2009). EASL clinical practice guidelines: management of cholestatic liver diseases. J. Hepatol. 51, 237–267. doi: 10.1016/j.jhep.2009.04.009

Warren, K. W., Athanassiades, S., and Monge, J. I. (1966). Primary sclerosing cholangitis. A study of forty-two cases. Am. J. Surg. 111, 23–38. doi: 10.1016/0002-9610(66)90339-4

Yeung, C., and Schooling, C. M. (2020). Systemic inflammatory regulators and risk of Alzheimer's disease: a bidirectional Mendelian-randomization study. Int. J. Epidemiol. [Preprint]. Available online at: https://academic.oup.com/ije/advance-article/doi/10.1093/ije/dyaa241/6032243 (accessed March 5, 2021).

Zhuang, Q., Shen, C., Wang, J., and Small, D. S. (2019). Powerful three-sample genome-wide design and robust statistical inference in summary-data Mendelian randomization. Int. J. Epidemiol. 48, 1478–1492. doi: 10.1093/ije/dyz142

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2021 Xie, Chen, Deng, Sun, Wang, Chen, Yuan and Hesketh. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.